glp-1 liver toxicity GLP-1s are back in the news — but this is a conversation we've explored on our channel before. From weight loss to heart, kidney, liver, sleep and metabolic health, the science is GLP1s may lower 10-year risk
Description
Between 2022 and early 2025, as the FDA permitted compounding pharmacies to produce these drugs under shortage conditions, a shadow market emerged offering semaglutide and tirzepatide through telehealth platforms for as little as $99$299 a month
Community endocrinologists and primary care physicians also favor prescribing to hospital pharmacies in some cases due to the latter's direct engagement with diabetes educators, nutritionists and other specialists
According to Google Trends, searches for "Wegovy" and "Ozempic" have skyrocketed since 2021
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis
GLP-1 therapy does not cause lactose intolerance, but alters the curve shape of the results
Regul Pept 2011;169:43-48
